Cargando…

Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer

Interferon-γ (IFNγ) is a cytokine with limited evidence of benefit in cancer clinical trials to date. However, it could potentially play a role in potentiating anti-tumor immunity in the immunologically "cold" metastatic castration-resistant prostate cancer (mCRPC) by inducing antigen pres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korentzelos, Dimitrios, Wells, Alan, Clark, Amanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033763/ https://www.ncbi.nlm.nih.gov/pubmed/35459800 http://dx.doi.org/10.1038/s41598-022-10724-9

Ejemplares similares

A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer
por: Korentzelos, Dimitrios, et al.
Publicado: (2020)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

Bone marrow involvement in patients with metastatic castration sensitive prostate cancer
por: Shahait, Mohammed, et al.
Publicado: (2022)

The cost impact of disease progression to metastatic castration-sensitive prostate cancer
por: Trinh, Quoc-Dien, et al.
Publicado: (2022)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
por: Meagher, Margaret F, et al.
Publicado: (2023)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
por: Pascoe, Abigail C, et al.
Publicado: (2012)

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
por: Parker, Daniel C., et al.
Publicado: (2020)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
por: Poon, Darren M.C., et al.
Publicado: (2015)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study
por: CAUBET, MATTHIEU, et al.
Publicado: (2015)

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
por: Pu, Yeong-Shiau, et al.
Publicado: (2022)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
por: Sims, Robert B.
Publicado: (2011)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
por: Podrazil, Michal, et al.
Publicado: (2015)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document
por: Lapini, Alberto, et al.
Publicado: (2019)

Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report
por: Daverede, Luis, et al.
Publicado: (2014)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan
por: Okumura, Hiroyuki, et al.
Publicado: (2021)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jd2ibnvt3usih2248cohb50f1h